Abstract: s: Objective To evaluate the efficacy and safety of tirofiban in the bridging therapy of mechanical thrombectomy after intravenous thrombolysis for acute ischemic stroke with main artery occlusion . Methods A retrospective analysis was performed on the clinical data of 121 patients diagnosed as acute ischemic stroke with main artery occlusion and treated with bridging therapy in the stroke database of our hospital from January 2016 to January 2019. 45 patients were treated with tirofiban during and after thrombectomy (tirofiban group), and 76 patients were not(standard treatment group). Baseline data of the two groups, scores of the National Institutes of Health Stroke Scale (NIHSS) 24 hours and 7 days after thrombectomy, Modified Rankin Score (mRS) scores at days 30 and days 90 , blood flow fractionation of Modified thrombolysis in myocardial infarction(mTICI) after thrombectomy, vascular re-occlusion rate, incidence of symptomatic intracranial hemorrhage(SICH), incidence of gastrointestinal hemorrhage and 3-month mortality were analyzed to assess the efficacy and safety of the two treatment options. Results The blood flow fractionation, 7-day NIHSS score, 30-day mRS score and 90-day mRS score of the tirofiban group were significantly better than those of the standard treatment group (P<0.05), while the SICH incidence, gastrointestinal hemorrhage incidence and 3-month mortality rate of the two groups were not statistically significant (P>0.05). Conclusion The use of tirofiban during and after the bridging therapy in patients of acute ischemic stroke with main artery occlusion can improve the vascular reperfusion, improve the prognosis and reduce the rate of vascular reocclusion without increasing the risk of bleeding.